You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The European Commission awarded a consortium of private companies and academic researchers €759,000 recently to carry out their plans.
The German biotech firm said its lateral flow blood test does not detect subclinical HPV infection but picks up on HPV-induced cancers and pre-cancers.
The xT platform integrates structured clinical patient data with results from a 648-gene DNA panel and whole-transcriptome RNA sequencing.
Cepheid said that the 4-in-1 test runs on any of almost 30,000 GeneXpert Systems, which provide results in approximately 36 minutes.
The Warsaw, Poland-based firm has secured nearly €20 million ($23.7 million) this year to advance its PCR One point-of-care molecular diagnostic system.
The kit is designed for use with samples stored in the company's CE-marked DNA/RNA Shield sample collection and preservation devices.
The firms said that the test would help Siolta identify and monitor patients eligible for its biotherapeutic therapy currently under development.
The advent of high-throughput antigen testing is especially timely as global regions are suffering second and third waves of infections during the coronavirus pandemic, Ortho said.
The firm CE marked its RespiFinder 2Smart kit for SARS-CoV-2 and MERS-CoV testing, as well as the RealAccurate Quadriplex Flu/COVID-19 PCR kit.
The test will identify patients with squamous cell head and neck cancer caused by specific HPV infections for treatment with BioNTech's investigational BNT113.